To examine the symptom burden in cancer patients during the last days of life, its impact on nutrition and hydration, and the role of artificial nutrition and hydration in the final days.
INTRODUCTION
Patients with advanced cancer often experience symptom distress throughout the disease trajectory starting from the time of diagnosis [1] . In the final weeks to months, many patients develop progressive functional decline and nutritional compromise associated with decreased ability and desire to eat/drink and weight loss [2] . During the last days of life, patients develop characteristic changes in their neurocognitive, neuromuscular, cardiovascular, and respiratory function [3, 4] .
There has been a paucity of studies on symptom prevalence during the last days of life [5] . This gap in knowledge is related to several unique challenges ( Table 1) . A better understanding of the symptom prevalence in the final days can help clinicians to educate patients and families what to expect, guide treatment recommendations, and identify opportunities for improvement in symptom management. In this article, we will provide a comprehensive literature review on symptom burden in cancer patients during the last days of life, its impact on nutrition and hydration, and the role of artificial nutrition and hydration for these patients.
SYMPTOM BURDEN DURING THE LAST DAYS OF LIFE
In a prospective study of 120 cancer patients in the Italian home care setting, Ventafridda et al. [15] reported that uncontrollable symptoms requiring sedation appeared in 63 (53%) patients on an average of 49 h before death, and included dyspnea (28%), pain (26%), delirium (9%), and vomiting (4%).
Fainsinger et al. conducted a retrospective study of 100 consecutive patients admitted to a palliative care unit for at least 6 days, and reported the symptom intensity of pain, nausea, and drowsiness during the last 7 days of life. The symptoms were assessed using a 0-100 visual analogue scale, and was completed by patients whenever possible (otherwise relatives or nurses). Drowsiness increased progressively, whereas pain and nausea improved close to death [16] .
Lichter et al. [9] examined the symptom burden among 200 consecutive patients who died in a hospice program in New Zealand. In this study, research nurses started documenting symptoms when patients were recognized as likely to die or after death if the death was unexpected. The most common symptoms during the last 48 h of life were noisy and moist breathing (56%), pain (51%), restlessness and agitation (42%), incontinence of urine (32%), difficulty in swallowing (29%), and dyspnea (22%). Patients enrolled in hospice care generally had good symptom control, which may partly explain the relatively low symptom prevalence.
In a prospective study, Conill et al. [10] reported the symptom prevalence during the last 7 days of ife in 176 consecutive patients with advanced cancer who died at home, in the hospital, or a hospice in Spain. Eighteen symptoms were assessed by clinicians as absent or present on first consultation and then during the last week of life (72% of the assessments were within the last 3 days of life). The mean time interval between study visits was 6.5 weeks. A majority of symptoms increased in frequency in the second visit, with anorexia (80%), dry mouth (70%), confusion (68%), constipation (55%), dyspnea (47%), dysphagia (46%), and anxiety (46%) being particularly common during the last 7 days.
In the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment study, 9105 patients with life-limiting illnesses (e.g., cirrhosis, chronic obstructive pulmonary disease, acute respiratory failure, multiple organ system failure with sepsis, colon, and nonsmall cell lung cancer, and heart failure) in the USA were observed from study entry at initial hospital admission until death or for up to 6 months [11] . Symptom burden during the last 3 days of life was assessed based on after-death interview with the patient's surrogate decision makers. Moderate to severe pain was reported in 34-45% of patients and dyspnea was reported in 28-83%. In this study, 80% had severe fatigue, 24-34% had confusion, 12% had nausea,
KEY POINTS
During the last days of life, cancer patients often experience progressive functional decline and worsening symptom burden. They often have decreased ability and desire to eat/drink. If desired, patients may try eating and/or drinking small amounts orally as tolerated with the goal of maximizing comfort while balancing the risk of complications (e.g., aspiration).
The use of artificial nutrition during the last days of life is not recommended because of the lack of confirmed benefit and likelihood of adverse effects.
A recent randomized controlled trial of parenteral hydration found no benefit compared with control when given to patients with only weeks of life expectancy; however, parenteral hydration is generally well tolerated and may be considered on a case-bycase basis.
The inability to eat and drink and body image changes at the end of life can be associated with significant distress. Education and counseling for patients and families are essential. 7] . Thus, few studies have examined patient-reported outcomes during this period. Moreover, clinicians often underestimate symptom burden, whereas caregivers often overestimate symptom intensity [8] .
The timing of death is challenging to predict, making it difficult to know when prospective data collection should be initiated. A majority of studies have either retrospectively reviewed data after patient's death, or started documenting when the patients were recognized as dying, which may introduce ascertainment bias and selection bias [9] [10] [11] [12] [13] .
Significant variations in study populations, methods to assess symptoms, and reporting of symptom burden make it challenging to compare study findings or combine the data.
Symptom prevalence varies widely by patient population (e.g., cancer vs. noncancer) and settings (e.g., hospice vs. acute hospital vs. nursing homes). For instance, patients with chronic obstructive pulmonary disease were much more likely to experience dyspnea at the end of life compared with patients with colon cancer [11] .
Some studies examined symptom prevalence (absent/present), a few only reported the frequency of moderate to severe symptoms, and others only provide symptom intensity.
The lack of investigators, research infrastructure, and funding likely further contributed to the limited research on the last days of life [14] .
Impact on nutrition and hydration in cancer patients Hui et al.
and approximately 25% had moderate to severe anxiety or dysphoria. McCarthy et al. [17] further reported the symptom trajectory among 316 patients with metastatic colon cancer and 747 patients with stage III/IV lung cancer in this study. Pain (45%), confusion (28%), depression, and anxiety increased steadily over the last 6 months of life, reaching a peak during the last 3 days of life.
Hall et al. [18] examined the symptom prevalence during the last 48 h of life among a convenience sample of 185 residents of long term care facilities in Canada. Sudden unexpected deaths were excluded. 14 (8%) patients had cancer. The investigators reported that dyspnea, pain, noisy breathing, delirium, dysphagia, fever, and myoclonus were documented in 62, 44, 39, 29, 28, 24, and 16% of patients during the last 48 h of life, respectively. Importantly, many symptoms may be underestimated in this retrospective chart review. The symptoms were documented by nursing staff alone 45-81% of the time, by physician alone 2-9% of the time, and by both 2-17% of the time.
In an Italian study, Toscani et al. [12] interviewed nurses within 72 h of death to document the symptom in 370 patients who died in general hospital wards (25% had cancer). 80 (22%) death were considered unexpected. The most common symptoms during the last day of life were reported to be fatigue (98%), drowsiness (78%), pain (75%), anorexia (73%), dyspnea (70%), incontinence (57%), and confusion (55%).
Veerbeek et al. [19] asked nurses to provide their assessment of patients' symptoms during the last 3 days of life within 1 week after death among patients who died in hospitals (n ¼ 11), nursing homes (n ¼ 102), and under home care (n ¼ 27). The questions were based on the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire. The investigators reported the average symptom intensity but not prevalence, with fatigue (61-73/100), lack of appetite (42-77/100), dyspnea (41-92/100), pain (38-58/100), and difficulty in concentrating (49-58/100) being the most significant concerns.
In a retrospective study conducted in Korea, Hwang et al. [13] reported the occurrence of 17 signs and symptoms as documented by the clinical team in 181 patients with advanced cancer who died in a palliative care unit and had medical records available for the final week. The symptoms confusion/ delirium, pain, dyspnea at rest, increasing sleep, general weakness, anxiety/depression, abdominal discomfort, nausea/vomiting, and poor appetite (finishing less than 1/3 of routine meal) were reported in 33, 24, 21, 12, 6, 6, 6, and 5% of patients during the last 48 h of life, respectively. The low frequency of symptoms relative to other studies may be related to the patient population, how the symptoms were defined, and the documentation process.
The Investigating the Process of Dying study is a prospective, longitudinal, and observational study that examined the symptom expression during the last week of life [6 && ]. The study included 357 consecutive patients with advanced cancer from two acute palliative care units, in which those who were able to communicate rated the average intensity of 10 symptoms over the past 24 h daily from admission until discharge or death using the Edmonton Symptom Assessment Scale. The symptom intensity was shown from death backwards, revealing that anorexia, drowsiness, well-being, fatigue, shortness of breath, and insomnia increased significantly in the final days of life ( Table 2 ). In the same study, the presence or absence of 15 other symptoms that could be observed were assessed by bedside nurses every 12 h from admission to discharge (regardless of communication capacity). Dysphagia to solids, dysphagia to liquids, urinary incontinence, and constipation had the highest frequency and continued to worsen during the last days of life (Table 3 ).
IMPACT OF SYMPTOMS ON NUTRITION AND HYDRATION DURING THE LAST DAYS OF LIFE
There are two major drivers of weight loss during the last days of life: starvation and refractory cachexia. As shown in Table 4 , patients experience significant symptom burden during the last days of life. Symptoms such as anorexia, dysphagia, weakness, and confusion often worsen as death approaches. These symptoms can have a major impact on nutrition and hydration ( Fig. 1 ), contributing either directly or indirectly to reduced oral intake, dehydration, weight loss, and decreased quality of life [20, 21] . Moreover, patients during the last days of life often have refractory cachexia with inflammatory response, hypermetabolism, and an overall catabolic state, resulting in persistent weight loss and functional decline even if the starvation component can be addressed [22] .
It is important for clinicians to recognize that a patient has reached the final phase of life, that many symptoms and/or acute complications may not be reversible even with aggressive interventions, and to communicate realistic expectations with patients and families [6 && ,23]. It often takes weeks for weight to improve even when patients present at earlier stages of cancer cachexia [24] . Thus, patients with refractory cancer and only days of survival are unlikely to benefit from nutritional/anticachexia interventions. Anorexia-cachexia is associated with a shorter life expectancy [25] ; however, it is unlikely that treatment of this syndrome, even if successful, would have any meaningful impact on survival because of the progressive cancer. In the following sections, we shall discuss the role of artificial nutrition and hydration during the last days of life and a practical approach to patient care taking into account the individual's prognosis.
THE ROLE OF ARTIFICIAL NUTRITION DURING THE LAST DAYS OF LIFE
Is there evidence to support artificial nutrition in patients with days of life expectancy? A Cochrane systematic review on artificial nutrition for palliative care patients identified no randomized controlled trials on this topic and only five prospective noncontrolled studies [26 & ]. Importantly, the survival of patients in all five studies was in terms of months instead of days. They concluded that there was insufficient evidence to make recommendations regarding artificial nutrition at the end of life. Another systematic review also highlighted the paucity of evidence to support that artificial nutrition can improve survival or quality of life [27] . Although there is a lack of research to support benefits of artificial nutrition, it is important to note that enteral and parenteral nutrition are invasive medical interventions that can cause significant complications. Adverse events associated with enteral feeding include pain and bleeding at the insertion site, tube blockage, diarrhea, constipation, aspiration, electrolyte deficiencies, hyperglycemia, refeeding syndrome, and tube feeding syndrome. Parenteral nutrition is also associated with many complications such as sepsis, hypoglycemia, hyperglycemia, hepatic dysfunction, electrolyte abnormalities, volume overload, and cholecystitis.
Other concerns related to artificial nutrition include the requirement for frequent monitoring and investigations and cost. The 2006 European Society for Clinical Nutrition and Metabolism guideline recommended against provision of enteral nutrition to patients with incurable cancer who were dying [28] . A separate European Society for Clinical Nutrition and Metabolism guideline suggested that parenteral nutrition should only be considered in patients with advanced cancer if life expectancy is at least 2-3 months, enteral nutrition is insufficient, parenteral nutrition is expected to stabilize or improve performance status and quality of life, and patient desires this mode of nutritional support [29] . The prognostic criterion is based on the observation that a healthy individual may live for 2-3 months without macronutrients [30] . Because cancer patients with shorter survival have competing risk factors for mortality, their survival is unlikely going to be improved even if reversal of starvation was successful.
THE ROLE OF ARTIFICIAL HYDRATION DURING THE LAST DAYS OF LIFE
Artificial hydration may be given enterally, subcutaneously, intravenously, or rectally. Unlike artificial nutrition that is generally not recommended during the last days of life, the decision to hydrate dying patients or not has been a topic of heated debate [31] . Proponents of artificial hydration stated that it is a basic human right (i.e., food) [32] , that hydration may alleviate thirst and other symptoms, reduce complications without significantly prolonging the dying process, and build rapport with family caregivers who often demand interventions. Opponents of artificial hydration believe that hydration may increase the risk of complications (e.g., edema, ascites, and pleural effusion), may introduce burden associated with need to urinate, does not improve quality of life, is not required in dying patients who do not complain of thirst, and may even interfere with the natural process of dying. The view of some healthcare professionals is that terminal dehydration could even lessen the burden of suffering [33] . Indeed, there is a wide variation in the prescription of artificial hydration among clinicians, which is driven by their beliefs toward the clinical/emotional benefits of hydration [34] .
The literature on artificial hydration during the last days of life is mixed, although no study has provided definitive evidence to support its use. In a before-and-after comparison, Bruera et al. [35] suggested that hydration coupled with opioid rotation may reduce the incidence of agitated delirium. Morita et al. [36] was not able to confirm this benefit in a study utilizing a similar design. Krishna et al. [37] conducted a retrospective cohort study [38] . However, a larger study that included 129 patients with longer duration of hydration revealed no difference in the same primary outcome by day 7 nor any secondary outcomes (symptoms, delirium, quality of life, creatinine, urea, or survival) [39 && ]. Because both studies excluded patients with severe dehydration and only provided hydration with 1 L of isotonic saline, future studies should examine if hydration could be beneficial for selected patients (e.g., severe hydration symptoms) or if given in a different manner (e.g., fluid type, fluid volume).
APPROACH TO HYDRATION AND NUTRITION DURING THE LAST DAYS OF LIFE
Patients and caregivers often perceive artificial nutrition and hydration to be beneficial, whereas health professionals are concerned about their sideeffects [40, 41] . As Koretz nicely stated, patients and families often worry about 'starving to death' and frequently get confused 'between dying in a malnourished state and dying as a direct consequence of nutrient deprivation; cancer patients fit into the former category' [42] . An interdisciplinary team consisting of physicians, nurses, psychologists, speech pathologists, physical/occupational therapists, and dieticians can provide appropriate education, gentle reassurance, emotional support, and nutritional guidance for patients during the last days and their families:
( (Table 5 ). There is no ethical distinction between withholding and withdrawing artificial nutrition. (7) Although there is also no definitive evidence to support that artificial hydration offers any benefits in this patient population, the adverse effects associated with hydration are generally limited. Thus, artificial hydration may be considered in selected patients after careful discussion of the risk, benefits, and goals of care. 
CONCLUSION
During the last days of life, cancer patients often experience progressive functional decline and worsening symptom burden. Many symptoms such as anorexia, dysphagia, and delirium could impair oral intake. These, coupled with refractory cachexia, contribute to persistent weight loss and decreased quality of life. Furthermore, the inability to eat and drink and body image changes may contribute to significant emotional distress among patients and caregivers. Clinicians caring for patients during the last days of life need to ensure impeccable communication about goals of care, education about the natural process of dying, optimization of symptom management balancing the risks, benefits, and limited prognosis, and provision of emotional support. There is currently a lack of evidence to support that artificial nutrition and hydration improve outcomes in patients during the last days of life; artificial nutrition is generally not recommended because of its invasive nature, whereas artificial hydration may be considered on a case-by-case basis.
